Opendata, web and dolomites

EVEREST SIGNED

Extracellular Vesicles for Bone Regeneration – alternatives to Stem-cell Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EVEREST project word cloud

Explore the words cloud of the EVEREST project. It provides you a very rough idea of what is the project "EVEREST" about.

elasticity    reduce    metabolic    harvest    answer    donors    mscs    induce    heterogeneity    soluble    exclusion    therapies    bioactive    constructs    intelligent    cargo    transport    acids    resection    proteins    tumors    permit    hypotheses    msc    sustained    hypoxia    platform    revolutionize    hypothesis    stress    therapeutic    cutting    frontier    environment    embark    regenerative    cells    modulate    breaking    progressing    replaced    ground    printing    nanoparticles    separates    stem    tested    fabricated    secreted    firstly    potent    vesicles    nucleic    free    medicine    potency    replacements    off    cell    favorable    benefits    questions    handle    shelf    edge    defects    vivo    evs    chromatography    release    manner    pain    cancerous    delineate    everest    attributed    mechanical    mesenchymal    size    harnessing    functionalized    dynamic    cues    anatomically    employed    answering    regeneration    trauma    correct    marrow    3d    substrate    extracellular    ev    critical    secretome    responsible    therapy    elimination    lipids    collection    treatment    healing    reported    human    bone    culture    diseases    environments   

Project "EVEREST" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙499˙925 €
 EC max contribution 1˙499˙925 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 1˙499˙925.00

Map

 Project objective

The therapeutic benefits of mesenchymal stem cells (MSCs), the state-of-the-art treatment for healing bone defects following trauma, resection of cancerous bone tumors, or metabolic bone diseases, has been attributed to their secreted factors. The regenerative potential of MSC-secreted extracellular vesicles (EVs), nanoparticles which deliver bioactive cargo (nucleic acids, proteins, and lipids) between cells, has recently been reported. The applicant will embark upon frontier research with the objective of progressing beyond the state-of-the-art, by harnessing the therapeutic effects of MSCs, but in a cutting-edge, cell-free manner, by developing high potency EV-based bone replacements. This objective will be addressed by firstly testing novel hypotheses to delineate how culture environments, specifically mechanical cues (substrate elasticity and 3D dynamic), hypoxia, and cell stress can modulate the cargo of EVs secreted by MSC. Size exclusion chromatography, which separates EVs from soluble proteins will be employed. Heterogeneity of EV cargo and functionality between human MSC donors will also be evaluated. Answering these hypotheses will permit the intelligent design of targeted EV therapies. The hypothesis that EV-functionalized constructs, fabricated by 3D-printing, will lead to controlled and sustained release of EVs and induce bone formation in vivo will best tested. Together, this will answer critical questions, namely the most favorable environment for collection of potent EVs for regenerative medicine, which secretome component (EV, soluble factors) is responsible for bone regeneration, and whether MSC cell therapy can be replaced by cell-free EVs. EVEREST will develop a platform for targeted EV delivery in ground-breaking, easy to transport and handle, ‘off-the-shelf’ anatomically correct constructs, which have the potential to reduce pain by elimination of bone or bone marrow harvest, and revolutionize the treatment of bone defects.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVEREST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVEREST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

QUAMAP (2019)

Quasiconformal Methods in Analysis and Applications

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More